
Illumina ILMN
$ 127.74
0.28%
Quarterly report 2025-Q3
added 10-31-2025
Illumina Accounts Payables 2011-2026 | ILMN
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Illumina
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 221 M | 245 M | 332 M | 192 M | - | 149 M | 184 M | 160 M | 139 M | - | 82.6 M | 73.7 M | 65.7 M | 66.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 332 M | 65.7 M | 159 M |
Quarterly Accounts Payables Illumina
| 2025-Q3 | 2025-Q2 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 218 M | 200 M | - | 199 M | 201 M | 244 M | 242 M | 293 M | - | 282 M | 291 M | 192 M | 248 M | 200 M | 178 M | - | 156 M | 135 M | 130 M | 149 M | 149 M | 149 M | 149 M | 184 M | 184 M | 184 M | 184 M | 160 M | 160 M | 160 M | 160 M | 139 M | 134 M | 251 M | 155 M | - | 123 M | 108 M | 107 M | 82.6 M | 82.6 M | 82.6 M | 82.6 M | 73.7 M | 73.7 M | 73.7 M | 73.7 M | 65.7 M | 65.7 M | 65.7 M | 65.7 M | 66.7 M | 52.2 M | 58.3 M | 66.3 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 293 M | 52.2 M | 148 M |
Accounts Payables of other stocks in the Diagnostics research industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Agilent Technologies
A
|
446 M | $ 114.84 | -0.55 % | $ 34.9 B | ||
|
Akumin
AKU
|
36.6 M | - | -17.87 % | $ 25.9 M | ||
|
Burning Rock Biotech Limited
BNR
|
63.1 M | $ 16.3 | 0.62 % | $ 175 M | ||
|
Aspira Women's Health
AWH
|
1.24 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
4.5 M | - | -61.36 % | $ 2.46 M | ||
|
Global Cord Blood Corporation
CO
|
8.33 M | - | - | $ 399 M | ||
|
Biocept
BIOC
|
1.52 M | - | -13.05 % | $ 7.29 M | ||
|
Biodesix
BDSX
|
2.19 M | $ 15.36 | 1.92 % | $ 1.99 B | ||
|
QIAGEN N.V.
QGEN
|
72.7 M | - | - | $ 10.6 B | ||
|
CareDx, Inc
CDNA
|
9.99 M | $ 17.82 | -2.68 % | $ 950 M | ||
|
Anixa Biosciences
ANIX
|
165 K | $ 2.59 | 1.57 % | $ 84.1 K | ||
|
Biomerica
BMRA
|
295 K | $ 2.17 | - | $ 4.98 M | ||
|
BioNano Genomics
BNGO
|
5.59 M | $ 1.15 | -4.17 % | $ 6.26 M | ||
|
Check-Cap Ltd.
CHEK
|
952 K | - | - | $ 9.42 M | ||
|
Co-Diagnostics
CODX
|
1.88 M | $ 4.4 | 101.83 % | $ 5.85 M | ||
|
Charles River Laboratories International
CRL
|
149 M | $ 168.22 | -3.26 % | $ 8.34 B | ||
|
Castle Biosciences
CSTL
|
6.9 M | $ 24.73 | -0.44 % | $ 687 M | ||
|
Celcuity
CELC
|
6.41 M | $ 114.22 | 1.41 % | $ 5.34 B | ||
|
Danaher Corporation
DHR
|
1.84 B | $ 192.12 | 0.53 % | $ 137 B | ||
|
DermTech
DMTK
|
1.48 M | - | -11.32 % | $ 2.94 M | ||
|
DexCom
DXCM
|
344 M | $ 63.21 | 1.59 % | $ 24.7 B | ||
|
Chembio Diagnostics
CEMI
|
3.34 M | - | 0.22 % | $ 16.8 M | ||
|
Enzo Biochem
ENZ
|
1.38 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
176 M | - | - | $ 19.8 B | ||
|
Quest Diagnostics Incorporated
DGX
|
307 M | $ 198.96 | 0.91 % | $ 22.1 B | ||
|
Fulgent Genetics
FLGT
|
18.4 M | $ 16.42 | -2.38 % | $ 496 M | ||
|
Guardant Health
GH
|
54.4 M | $ 89.66 | -4.44 % | $ 11.2 B | ||
|
Heska Corporation
HSKA
|
16.4 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
1.16 M | - | -20.0 % | $ 1.06 M | ||
|
ICON Public Limited Company
ICLR
|
173 M | $ 109.62 | -4.0 % | $ 9.04 B | ||
|
Interpace Biosciences
IDXG
|
983 K | $ 1.97 | 0.63 % | $ 8.72 M | ||
|
IQVIA Holdings
IQV
|
322 M | $ 170.72 | -1.47 % | $ 29.3 B | ||
|
Laboratory Corporation of America Holdings
LH
|
841 M | $ 274.46 | 0.27 % | $ 22.8 B | ||
|
Lantheus Holdings
LNTH
|
42.9 M | $ 75.89 | -0.28 % | $ 5.12 B | ||
|
Medpace Holdings
MEDP
|
28.1 M | $ 496.0 | -0.47 % | $ 14.3 B | ||
|
Mettler-Toledo International
MTD
|
267 M | $ 1 266.63 | 0.53 % | $ 26.1 B | ||
|
Myriad Genetics
MYGN
|
30 M | $ 4.67 | -1.68 % | $ 432 M | ||
|
ENDRA Life Sciences
NDRA
|
383 K | $ 4.74 | 1.07 % | $ 3.73 M | ||
|
NeoGenomics
NEO
|
23.1 M | $ 8.02 | 0.25 % | $ 1.03 B | ||
|
Neogen Corporation
NEOG
|
79.6 M | $ 9.56 | 1.59 % | $ 2.07 B | ||
|
National Research Corporation
NRC
|
1.17 M | $ 17.33 | 0.99 % | $ 388 M |